Johannes Schetelig Selected Research

fludarabine

1/2020	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
8/2015	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire.
3/2010	188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
9/2008	Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
10/2002	The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johannes Schetelig Research Topics

Disease

36	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2022 - 09/2008
19	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 03/2002
18	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2022 - 05/2007
16	Neoplasms (Cancer) 02/2022 - 03/2010
12	Leukemia 01/2022 - 11/2005
11	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 01/2009
6	Infections 01/2020 - 11/2005
3	Disease Progression 01/2020 - 02/2015
3	Multiple Myeloma 01/2020 - 11/2016
3	Lymphoma (Lymphomas) 12/2019 - 10/2002
2	Bronchiolitis Obliterans Syndrome 01/2022 - 03/2002
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 11/2005
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2021 - 12/2020
2	COVID-19 04/2021 - 01/2021
2	B-Cell Lymphoma (Lymphoma, B Cell) 12/2019 - 01/2018
2	Pathologic Complete Response 12/2019 - 11/2019
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 12/2019 - 04/2004
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2019 - 01/2019
2	Iron Overload 05/2018 - 12/2012
2	Tumor Lysis Syndrome 01/2017 - 03/2014
2	Acute Kidney Injury (Acute Renal Failure) 01/2017 - 01/2009
2	Residual Neoplasm 07/2013 - 11/2009
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2009 - 09/2008
1	Disseminated Intravascular Coagulation 01/2021
1	Body Weight (Weight, Body) 01/2021
1	Hemorrhagic Disorders (Hemorrhagic Diathesis) 01/2021
1	Clostridium Infections 01/2020
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2020
1	Enterocolitis 01/2020
1	Opportunistic Infections (Opportunistic Infection) 01/2019
1	Primary Myelofibrosis (Myelosclerosis) 01/2019
1	Cytomegalovirus Infections (Inclusion Disease) 01/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2019
1	Hyperuricemia 01/2017

Drug/Important Bio-Agent (IBA)

5	fludarabineIBA 01/2020 - 10/2002
4	idelalisibIBA 02/2022 - 12/2020
4	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 03/2002
4	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2019 - 07/2011
4	Alemtuzumab (Campath)FDA Link 10/2015 - 04/2004
3	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 09/2012
3	Peptides (Polypeptides)IBA 01/2021 - 06/2011
3	purineIBA 11/2019 - 12/2014
3	NucleophosminIBA 01/2018 - 03/2016
2	Tacrolimus (Prograf)FDA LinkGeneric 01/2022 - 01/2009
2	Calcineurin InhibitorsIBA 01/2022 - 01/2009
2	EpitopesIBA 01/2021 - 02/2018
2	Minor Histocompatibility AntigensIBA 01/2021 - 04/2012
2	Busulfan (Busulfex)FDA Link 01/2020 - 03/2010
2	ibrutinibIBA 01/2020 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 02/2018 - 11/2016
2	venetoclaxIBA 01/2018 - 06/2016
2	Clofarabine (Clolar)FDA Link 12/2017 - 06/2016
2	rasburicase (Elitek)FDA Link 01/2017 - 03/2014
2	RheniumIBA 10/2015 - 03/2010
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2012 - 03/2002
2	Cidofovir (Vistide)FDA Link 06/2007 - 01/2007
2	Foscarnet FDA LinkGeneric 06/2007 - 04/2004
1	trans-crotonin (CTN)IBA 01/2022
1	isocitric acid (isocitrate)IBA 01/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 12/2021
1	CPX-351IBA 10/2021
1	CC ChemokinesIBA 04/2021
1	plerixafor FDA Link 01/2021
1	Decitabine FDA Link 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Dacarbazine (DIC)FDA LinkGeneric 01/2021
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	HLA-A Antigens (HLA-A)IBA 01/2021
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2021
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2021
1	treosulfanIBA 01/2020
1	Core Binding Factors (Core-Binding Factor)IBA 01/2020
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2020
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 12/2019
1	Immunosuppressive Agents (Immunosuppressants)IBA 12/2019
1	Cisplatin (Platino)FDA LinkGeneric 12/2019
1	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 12/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019
1	IronIBA 05/2018
1	ProteomeIBA 02/2018
1	serum P-component (CIt)IBA 01/2018
1	Phosphotransferases (Kinase)IBA 10/2017
1	Urate Oxidase (Uricase)IBA 01/2017
1	Hyaluronic Acid (Hyaluronan)IBA 11/2016
1	AntigensIBA 11/2016

Therapy/Procedure

26	Stem Cell Transplantation 02/2022 - 11/2003
21	Hematopoietic Stem Cell Transplantation 01/2022 - 11/2005
21	Cell Transplantation 01/2022 - 09/2008
16	Therapeutics 06/2022 - 04/2004
13	Transplantation 01/2021 - 09/2008
5	Drug Therapy (Chemotherapy) 01/2022 - 11/2003
4	Salvage Therapy 01/2022 - 09/2008
4	Radioimmunotherapy 01/2020 - 03/2010
3	Homologous Transplantation 01/2019 - 03/2002
1	Blood Component Removal (Apheresis) 01/2021
1	Donor Selection 01/2020
1	Long-Term Care 01/2019
1	Immunotherapy 02/2018